WHO advises additional COVID shot for immunocompromised people
- Wall St ends up with Goldman; Dow posts biggest weekly rise since June
- Goldman Sachs (GS) Smashes Analyst 3Q Views on Robust M&A and Underwriting Activity
- Tesla (TSLA) Stock: Jefferies Raises Price Target on Higher Capacity Ramp and Sustained Demand, Berlin Giga Will Set New Design and Assembly Standards Says Analyst
- Food, fuels lift U.S. import prices in September
- SEC to Allow First Ever Bitcoin (BTC) ETF - Report
FILE PHOTO: A logo is pictured at the World Health Organization (WHO) building in Geneva, Switzerland, February 2, 2020. REUTERS/Denis Balibouse
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
By Stephanie Nebehay and Emma Farge
GENEVA (Reuters) -The World Health Organization on Monday recommended that immunocompromised people be given an additional dose of COVID-19 vaccine, due to their higher risk of breakthrough infections after standard immunisation.
The Strategic Advisory Group of Experts on immunisation said the additional dose should be offered "as part of an extended primary series since these individuals are less likely to respond adequately to vaccination following a standard primary vaccine series and are at high risk of severe COVID-19 disease".
WHO vaccine director Kate O'Brien, referring to people with lower immunity due to other conditions, told a news briefing: "The recommendation is for a third vaccination, an additional vaccination in the primary series and again that is based on the evidence showing that the immunogenicity and evidence on breakthrough infections is highly disproportionately represented by those people."
The panel also recommended that people over 60 receive an additional dose of the shots made by Chinese vaccine makers Sinopharm and Sinovac some one to three months after completing their schedule, citing evidence in studies in Latin America that they perform less well over time.
Observational data on Sinopharm and Sinovac shots "clearly showed that in older age groups ... the vaccine performs less well after two doses", said Joachim Hombach, secretary of the independent panel of experts who held a five-day closed-door meeting last week.
"We also know that the addition of a third dose or moving into a two-plus-one schedule provides a strong (immune) response. So we expect from there a much better protection," he said.
Health authorities using the Sinopharm and Sinovac vaccines should aim first to maximise two-dose coverage in the older populations and then administer the third dose, the panel said.
The SAGE group, composed of independent experts who make policy but not regulatory recommendations, will review all global data on booster shots in a Nov. 11 meeting, amid questions over variants and potential waning of immunity, O'Brien said.
Currently some 3.5 billion doses of COVID-19 vaccines have been administered, O'Brien said.
An estimated 1.5 billion doses are available globally each month, enough to meet the target of vaccinating 40% of each country's population by year-end, but distribution is unequal, she added.
"Giving those booster doses to individuals who have already had the benefit of a primary response is like putting two life jackets on somebody and leaving others without any lifejacket," O'Brien said.
"In this sense we are talking about getting the first lifejacket onto people who have immunocompromising conditions."
(Reporting by Stephanie Nebehay and Emma Farge; Editing by Catherine Evans)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. FDA considering lowering recommended age for Pfizer/BioNTech COVID-19 boosters
- U.S. donates 17 million J&J doses to African Union
- Johnson & Johnson's (JNJ) Subsidiary Created For Talc Litigations Files for Chapter 11 Bankruptcy
Create E-mail Alert Related CategoriesFDA, General News, Reuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!